18/02/09

Eliminating lymphatic filariasis: We’re not there yet

The leg of a patient suffering from lymphatic filariasis Copyright: WHO/TDR/Crump

We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:

You have to credit our authors.
You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
The easiest way to get the article on your site is to embed the code below.

For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

<div class="article-wrap">
<div id="article-introduction">
<h1>Eliminating lymphatic filariasis: We’re not there yet</h1>
<h4></h4>
</div>
<br />
<br />

<div id="article-body">
<p><span>Ten years on, the Global Programme to Eliminate Lymphatic Filariasis (GPELF) deserves praise, says David H. Molyneux. But there is still some way to go before we eliminate the disease — complacency is out of the question, he adds. </span></p>
<p><span>Donations of key drugs from large pharmaceutical companies — notably GlaxoSmithKline and Merck & Co Inc — have done much to help the GPELF. Around 1.3 billion donated tablets have been distributed, and a further 4.65 billion bought. At the end of 2007, 48 countries had active treatment programmes for lymphatic filariasis and the GPELF has reached more than half a billion people. </span></p>
<p><span>And it has brought many indirect benefits, says Molyneux. In Sub-Saharan Africa and Asia, the GPELF has provided a platform for other neglected disease programmes including schistosomiasis and onchocerciasis. De-worming, carried out by the GPELF, also has positive effects on anaemia, nutrition, growth and cognitive function. </span></p>
<p><span>China and South Korea have eliminated the disease. But 81 countries still remain endemic. While the GPELF is a key component of the global movement against neglected tropical diseases, the ultimate objective to eliminate lymphatic filariasis must remain at the forefront of the GPELF’s vision.</span></p>
<p><span><a href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2809%2960181-1/fulltext" target="_blank" rel="noopener noreferrer">Link to full article in <em>The Lancet</em></a>*</span></p>
<div>
<p><span>*Free registration is required to view this article</span></p>
</div>

</div>
<div class="quick-links-wrapper">
<h3>You might also like</h3>
[related-articles]
</div>
<p>This article was originally published on <a href="https://www.scidev.net" target="_blank">SciDev.Net</a>. Read the <a href="https://www.scidev.net/global/opinions/eliminating-lymphatic-filariasis-we-re-not-there-y/" target="_blank">original article</a>.</p>
<script type="text/javascript">
(function(e,t,n,r,i,s,o){e["GoogleAnalyticsObject"]=i;e[i]=e[i]||function(){(e[i].q=e[i].q||[]).push(arguments)},e[i].l=1*new Date;s=t.createElement(n),o=t.getElementsByTagName(n)[0];s.async=1;s.src=r;o.parentNode.insertBefore(s,o)})(window,document,"script","//www.google-analytics.com/ga.js","ga");var _gaq=_gaq||[];var _gaq=_gaq||[];_gaq.push(["_setAccount","UA-3223906-8"],["_trackEvent","article interaction","republished","https://www.scidev.net/global/opinions/eliminating-lymphatic-filariasis-we-re-not-there-y/",null,true])
</script>
</div>

Ten years on, the Global Programme to Eliminate Lymphatic Filariasis (GPELF) deserves praise, says David H. Molyneux. But there is still some way to go before we eliminate the disease — complacency is out of the question, he adds.

Donations of key drugs from large pharmaceutical companies — notably GlaxoSmithKline and Merck & Co Inc — have done much to help the GPELF. Around 1.3 billion donated tablets have been distributed, and a further 4.65 billion bought. At the end of 2007, 48 countries had active treatment programmes for lymphatic filariasis and the GPELF has reached more than half a billion people.

And it has brought many indirect benefits, says Molyneux. In Sub-Saharan Africa and Asia, the GPELF has provided a platform for other neglected disease programmes including schistosomiasis and onchocerciasis. De-worming, carried out by the GPELF, also has positive effects on anaemia, nutrition, growth and cognitive function.

China and South Korea have eliminated the disease. But 81 countries still remain endemic. While the GPELF is a key component of the global movement against neglected tropical diseases, the ultimate objective to eliminate lymphatic filariasis must remain at the forefront of the GPELF’s vision.

Link to full article in The Lancet*

*Free registration is required to view this article